Company: ZLAB
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001628280-25-008409
Chunk: 101

Company: Zai Lab Ltd
Filing Date: 2025-02-27
Form: 10-K
Item: Item 1
Chunk 101
---
 MarketsPartnerOncology PipelineBemarituzumabAnti-FGFR2b antibody1L Gastric/GEJ Cancer – Phase III (FORTITUDE-101 and FORTITUDE-102)Greater ChinaFive Prime (now owned by Amgen)Tumor Treating FieldsPortable device for delivery of electric fields2L+ NSCLC – Phase III (LUNAR) Pancreatic Cancer – Phase III (PANOVA-3) Greater ChinaNovoCureTisotumab vedotin (TIVDAK)Tissue Factor ADC2L+ Cervical Cancer – Phase III   (innovaTV 301)1L r/m Cervical Cancer - Phase II (innovaTV 205)Greater ChinaSeagen (now owned by Pfizer)Repotrectinib (AUGTYRO)TKI targeting ROS1 oncogenic fusionsNTRK+ Solid Tumors – Phase I/II (TRIDENT-1)Greater ChinaTurning Point (now owned by BMS)Immunology, Neuroscience, and Infectious Disease PipelineEfgartigimod (VYVGART, VYVGART Hytrulo, Pre-Filled Syringe)FcRn blockerTED – Phase III (UplighTED)Myositis - Phase III (ALKIVIA)sn-gMG - Phase III (ADAPT-SERON)Ocular MG - Phase III (ADAPT-OCULUS)LN - Phase IIGreater ChinaargenxXanomeline and Trospium Chloride (COBENFY, KarXT)Combination of muscarinic receptor agonist and antimuscarinic agent Schizophrenia – Phase III (EMERGENT) ADP – Phase III (ADEPT-2 and ADEPT-3)Greater ChinaKaruna (now owned by BMS)

The following sections include more information on significant product candidates in our oncology and immunology, neuroscience, and infectious disease pipelines. For more information on license agreements for our significant product candidates, see Overview of Significant License and Collaboration Agreements; for more information on how we source our product candidates, see Manufacturing, Suppliers, and Quality Control; and for information on 

-6-

risks related to our potential products and R&D activities, including clinical trials and reliance on third parties, see Risk Factors.

Our Oncology Pipeline

ZL-1310 (DLL3 ADC)

ZL-1310 is a potential